Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL

Trial Profile

AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2019

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 13 Feb 2018 Planned End Date changed from 28 Feb 2019 to 24 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top